Among the five candidate DMT targets and revealed that TPP1 was significantly upregulated in late-stage PD (adjusted p-value = 0.0026; log2 fold change = 0.35) (Fig. 5A and B), while no significant differential expression was observed in early-stage PD (Supplementary Fig. 3). The gene discussed is TPP1; the disease is Parkinson disease.